MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

118.93
-1.23
-1.02%
After Hours: 118.93 0 0.00% 16:10 08/05 EDT
OPEN
120.00
PREV CLOSE
120.16
HIGH
120.87
LOW
118.02
VOLUME
849.07K
TURNOVER
--
52 WEEK HIGH
136.27
52 WEEK LOW
72.14
MARKET CAP
11.04B
P/E (TTM)
56.48
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBIX stock price target is 140.29 with a high estimate of 161.00 and a low estimate of 120.00.

EPS

NBIX News

More
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
NBIX earnings call for the period ending June 30, 2020.
Motley Fool · 1d ago
Credit Suisse Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $126
Credit Suisse analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and lowers the price target from $135 to $126.
Benzinga · 1d ago
Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $146
Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $149 to $146.
Benzinga · 1d ago
How Neurocrine Biosciences Crushed It in Q2
Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.
Motley Fool · 1d ago
JP Morgan Downgrades Neurocrine Biosciences to Neutral, Announces $136 Price Target
JP Morgan analyst Anupam Rama downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Neutral and announces $136 price target.
Benzinga · 1d ago
Neurocrine Bio beats Q2 views on strong Ingrezza sales
Neurocrine Biosciences (NASDAQ:NBIX) Q2 results: Revenues: $302.4M (+64.8%); Ingrezza sales: $267.6M (+48.2%). Net income: $79.6M (+55.2%); non-GAAP net in
seekingalpha · 1d ago
Neurocrine Biosciences EPS beats by $0.40, beats on revenue
Neurocrine Biosciences (NASDAQ:NBIX): Q2 Non-GAAP EPS of $1.42 beats by $0.40; GAAP EPS of $0.81 beats by $0.15. Revenue of $302.4M (+64.7% Y/Y) beats by $
seekingalpha · 1d ago
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago

Industry

Biotechnology & Medical Research
+0.15%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Symbol
Price
%Change

About NBIX

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.